晚期霍奇金淋巴瘤大淋巴结肿块在ABVD后完全代谢缓解可安全省略巩固放疗:GITIL/FIL HD0607随机试验最终分析
HD0607试验纳入晚期霍奇金淋巴瘤且基线有大淋巴结肿块(≥5 cm)、ABVD两周期和六周期后PET均阴性的患者,随机接受巩固放疗或不进一步治疗。中位随访5.9年,各肿块大小亚组的6年无进展生存率在巩固放疗与不治疗间均无显著差异,提示可安全省略巩固放疗。
要点
- 基线大淋巴结肿块(≥5 cm)且PET-2和PET-6均阴性的晚期霍奇金淋巴瘤患者可安全省略巩固放疗。
- 巩固放疗中位剂量30.6 Gy(范围24-36 Gy),各亚组6年无进展生存率与不治疗组无显著差异。
- 省略巩固放疗的结论不受基线大淋巴结肿块大小影响。
核心结论
- 对于基线有大淋巴结肿块且PET-2和PET-6均阴性的晚期霍奇金淋巴瘤患者,可安全省略巩固放疗,不受基线肿块大小影响。
研究设计与样本
- HD0607随机试验纳入晚期(IIB-IVB)霍奇金淋巴瘤患者,基线有大淋巴结肿块(最大直径≥5 cm)且ABVD两周期和六周期后PET均阴性,随机接受巩固放疗或不进一步治疗。
- 共296例随机分组患者,基线肿块最大直径5-7 cm者101例(34%,亚组A),8-10 cm者96例(32%,亚组B),经典巨块(>10 cm)者99例(33%,亚组C)。
关键数值与推荐
- 大淋巴结肿块定义为基线最大直径≥5 cm。
- 巩固放疗中位剂量30.6 Gy(范围24-36 Gy)。
临床怎么用
- 对ABVD后PET-2和PET-6均阴性的晚期霍奇金淋巴瘤伴基线大淋巴结肿块患者,可考虑省略巩固放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the role of consolidation radiotherapy (cRT) in advanced-stage Hodgkin lymphoma (HL) presenting at baseline with a large nodal mass (LNM) in complete metabolic response after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. PATIENTS AND METHODS: Advanced-stage (IIB-IVB) HL patients, enrolled in the HD 0607 trial (Clinicaltrial.gov identifier NCT00795613), with both a negative PET after two (PET-2) and six (PET-6) ABVD cycles, who presented at baseline with an LNM, defined as a nodal mass with the largest diameter ≥ 5 cm, were prospectively randomly assigned to receive cRT over the LNM or no further treatment (NFT). RESULTS: Among 296 randomly assigned patients, the largest diameter of LNM at baseline was 5-7 cm in 101 (34%; subgroup A) and 8-10 cm in 96 (32%; subgroup B), whereas classic bulky (diameter > 10 cm) was detected in 99 (33%; subgroup C). Two hundred eighty patients (88%) showed a postchemotherapy RM. The median dose of cRT was 30.6 Gy (range, 24-36 Gy). After a median follow-up of 5.9 years (range, 0.5-10 years), the 6-year progression-free survival rate of patients who underwent cRT or NFT was, respectively, 91% (95% CI, 84% to 99%) and 95% (95% CI, 89% to 100%; P = .62) in subgroup A; 98% (95% CI, 93% to 100%) and 90% (95% CI, 80% to 100%; P = .24) in subgroup B; 89% (95% CI, 81% to 98%) and 86% (95% CI, 77% to 96%; P = .53) in subgroup C (classic bulky). CONCLUSION: cRT could be safely omitted in patients with HL presenting with an LNM and a negative PET-2 and PET-6 scan, irrespective from the LNM size detected at baseline.
引用
- Gallamini A, Rossi A, Patti C, et al. Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. J Clin Oncol. 2020. PMID: 32946355. doi:10.1200/JCO.20.00935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。